{"id":"W3164306653","doi":"10.1136/annrheumdis-2021-eular.473","title":"OP0144 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 1-YEAR RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH OPEN-LABEL EXTENSION","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta","funders":"Friedrich-Alexander-Universität Erlangen-Nürnberg; Gilead Sciences; Sanofi; Chugai Pharmaceutical; Pfizer; Universitätsklinikum Erlangen; Eli Lilly and Company","keywords":"Medicine; BASDAI; Ankylosing spondylitis; Adverse effect; BASFI; Placebo; Internal medicine; Tolerability; Contraindication; Arthritis; Psoriatic arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003357362,0.001808894,0.005306708,0.000666439,0.0006203321,0.001699819,0.001146383,0.002655097,0.005108376],"category_scores_gemma":[0.002463272,0.0009019601,0.004094338,0.0007455879,0.001815932,0.002233228,0.0006046137,0.004160373,0.0009517563],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008392787,"about_ca_system_score_gemma":0.00130912,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008968624,"about_ca_topic_score_gemma":0.001570786,"domain_scores_codex":[0.9986995,0.00059023,0.0001095351,0.0002044765,0.0001403659,0.0002558139],"domain_scores_gemma":[0.9984424,0.0004806473,0.0003864851,0.0001466777,0.0001547384,0.0003891551],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9750734,0.005406932,0.0008339853,0.0006215315,0.001300098,0.000037019,0.00003397365,0.0002141896,0.001941007,0.00004738939,0.0003664314,0.01412389],"study_design_scores_gemma":[0.9169516,0.07421926,0.005683198,0.0000484546,0.001735677,0.0000490187,0.00003400122,0.0003087485,0.0005383508,0.00007257766,0.0003259247,0.00003314536],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9870345,0.008409169,0.0004736497,0.0003821797,0.0003741886,0.001063029,0.0009599259,0.00009867557,0.001204607],"genre_scores_gemma":[0.9908298,0.003577063,0.0006986908,0.0005908499,0.0004348779,0.0008952536,0.001646184,0.00002559647,0.001301662],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005306708,"threshold_uncertainty_score":0.01775569,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04531372939620665,"score_gpt":0.3208458371285809,"score_spread":0.2755321077323742,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}